GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » WACC %

Moleculin Biotech (Moleculin Biotech) WACC % :14.92% (As of May. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech WACC %?

As of today (2024-05-25), Moleculin Biotech's weighted average cost of capital is 14.92%%. Moleculin Biotech's ROIC % is -235.03% (calculated using TTM income statement data). Moleculin Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Moleculin Biotech WACC % Historical Data

The historical data trend for Moleculin Biotech's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech WACC % Chart

Moleculin Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
WACC %
Get a 7-Day Free Trial Premium Member Only 12.27 14.58 13.05 14.75 13.82

Moleculin Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.46 11.17 13.06 13.82 14.23

Competitive Comparison of Moleculin Biotech's WACC %

For the Biotechnology subindustry, Moleculin Biotech's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moleculin Biotech's WACC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's WACC % distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's WACC % falls into.



Moleculin Biotech WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Moleculin Biotech's market capitalization (E) is $11.396 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2024, Moleculin Biotech's latest one-year quarterly average Book Value of Debt (D) is $0.4456 Mil.
a) weight of equity = E / (E + D) = 11.396 / (11.396 + 0.4456) = 0.9624
b) weight of debt = D / (E + D) = 0.4456 / (11.396 + 0.4456) = 0.0376

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.467%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Moleculin Biotech's beta is 1.84.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.467% + 1.84 * 6% = 15.507%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2024, Moleculin Biotech's interest expense (positive number) was $-0 Mil. Its total Book Value of Debt (D) is $0.4456 Mil.
Cost of Debt = -0 / 0.4456 = 0%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -26.824 = 0%.

Moleculin Biotech's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9624*15.507%+0.0376*0%*(1 - 0%)
=14.92%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moleculin Biotech  (NAS:MBRX) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Moleculin Biotech's weighted average cost of capital is 14.92%%. Moleculin Biotech's ROIC % is -235.03% (calculated using TTM income statement data). Moleculin Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Moleculin Biotech (Moleculin Biotech) Business Description

Traded in Other Exchanges
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.
Executives
Jonathan P. Foster officer: Exec. Vice President and CFO 2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp director, 10 percent owner, officer: Chairman and Acting CEO 1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe 10 percent owner 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco director PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut director 2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker 10 percent owner, officer: President and COO
Michael D Cannon director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth officer: Chief Financial Officer 2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380

Moleculin Biotech (Moleculin Biotech) Headlines

From GuruFocus